Compare · PASG vs TSHA
PASG vs TSHA
Side-by-side comparison of Passage Bio Inc. (PASG) and Taysha Gene Therapies Inc. (TSHA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PASG and TSHA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- TSHA is the larger of the two at $1.64B, about 115.0x PASG ($14.2M).
- Over the past year, PASG is down 17.1% and TSHA is up 146.8% - TSHA leads by 163.9 points.
- TSHA has been more active in the news (10 items in the past 4 weeks vs 4 for PASG).
- TSHA has more recent analyst coverage (17 ratings vs 12 for PASG).
- Company
- Passage Bio Inc.
- Taysha Gene Therapies Inc.
- Price
- $4.91+11.73%
- $6.20+8.78%
- Market cap
- $14.2M
- $1.64B
- 1M return
- -12.57%
- +8.68%
- 1Y return
- -17.08%
- +146.81%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2020
- News (4w)
- 4
- 10
- Recent ratings
- 12
- 17
Passage Bio Inc.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase (Ã-gal) for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin, or GRN, gene encoding progranulin, or PGRN, for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A, as well as programs for the treatment of adult CNS indication. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
Taysha Gene Therapies Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas.
Latest PASG
- Large owner Lynx1 Capital Management Lp bought $206,101 worth of shares (50,055 units at $4.12) (SEC Form 4)
- SEC Form 425 filed by Passage Bio Inc.
- SEC Form 425 filed by Passage Bio Inc.
- Passage Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Passage BIO downgraded by Guggenheim
- Passage Bio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
- Passage Bio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Sondhi Dolan
- SEC Form 4 filed by Director Porter Derrell
- SEC Form 4 filed by Director Kassberg Thomas Richard
Latest TSHA
- President and Head of R&D Nagendran Sukumar sold $1,248,000 worth of shares (200,000 units at $6.24) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 936,410 units (SEC Form 4)
- SEC Form 144 filed by Taysha Gene Therapies Inc.
- SEC Form 8-K filed by Taysha Gene Therapies Inc.
- SEC Form 424B5 filed by Taysha Gene Therapies Inc.
- Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
- Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
- SEC Form 424B5 filed by Taysha Gene Therapies Inc.
- Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Taysha Gene Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome